Ardelyx Forecasts Over $500M in Revenue as IBSRELA Drives Growth
Ardelyx (NASDAQ:ARDX) forecasts revenue of over $500 million for 2026, driven primarily by its product IBSRELA. The company expects IBSRELA to generate between $410 million and $430 million in revenue this year due to expanded sales efforts and improved prescription fulfillment.
Tickers: $ARDX
Topics: biotech IBS-C treatment pharmaceuticals profitability outlook